Bridging the Gap Between In Vitro and In Vivo with CETSA
4 March 2025
17:00 CET | 16:00 GMT | 11:00 EST | 08:00 PST
Translating early drug discovery into clinical success is one of the biggest challenges in drug development. Ensuring that target engagement observed in vitro holds true in vivo is critical for making informed decisions.
In this exclusive webinar, Jon Ellery, Director of Biology at Sitryx Therapeutics, will share how Sitryx leveraged Pelago Bioscience’s CETSA technology to assess target engagement and improve translational confidence in drug discovery.
What You’ll Learn
- How CETSA enables better decision-making – Understand how CETSA helped Sitryx confirm target engagement and optimize small molecule development.
- Validating in vivo target engagement – See how CETSA provided crucial insights for bridging the gap between in vitro and in vivo studies.
- Real-world case study with Sitryx – Get a step-by-step look at how CETSA was applied to a promising drug candidate.
Featured Speaker
Jonathan Ellery
Director of Biology, Sitryx Therapeutics
Jon Ellery is a seasoned expert in analytical pharmacology and translational research, with extensive experience in drug discovery and small molecule development. With a background at Takeda, Cancer Research UK, and now Sitryx Therapeutics, Jon has been instrumental in ensuring confidence in early-stage drug development.
